Recor Medical Completes First Commercial Cases with Renal Denervation System

Recor Medical announced the first commercial cases of its Paradise ultrasound renal denervation (uRDN) system to treat hypertension.
 
The first commercial procedures took place at NewYork-Presbyterian/Columbia University Irving Medical Center in New York City by Drs. Ajay J. Kirtane and Sahil A. Parikh; at the Smidt Heart Institute at Cedars-Sinai in Los Angeles by Drs. Suhail Dohad and Raj Makkar; at Gates Vascular Institute in Buffalo, NY by Dr. Vijay Iyer; and Cleveland Clinic by Dr. Aravinda Nanjundappa.
 
Paradise earned U.S. Food and Drug Administration (FDA) approval last week as a first-of-its kind ultrasound-based RDN technology. It lowers blood pressure by denervating overactive sympathetic nerves around the renal arteries, delivering two to three doses of 360-degree ultrasound energy (which last seen seconds each) through the main renal arteries to surrounding nerves.
 
Its catheter features HydroCooling, circulation of sterile water through the balloon to cool and protect the renal artery’s inner layers.
 
“This new renal denervation technology for a high-risk patient population—individuals with difficult to control hypertension—has been long awaited. We look forward to offering this procedure now to those that will likely derive benefit,” Dr. Nanjundappa told the press.
 
The Paradise system is now available as an adjunct treatment option for patients who have been unable to achieve blood pressure goals with standard lifestyle changes and oral medications.